Clinical Trial Update: Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sorafenib with gemcitabine and capecitabine in unresectable or metastatic renal cell carcinoma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Gemcitabine (Gemcitabine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-04-06